Multi-arm PEG derivatives market seen reaching $10.5 billion by 2030

By AI, Created 6:21 PM UTC, May 29, 2026, /AGP/ – The Business Research Company says the multi-arm polyethylene glycol derivatives market will climb from $6.72 billion in 2026 to $10.5 billion by 2030, driven by drug delivery, regenerative medicine and personalized medicine demand. North America led the market in 2025, while Asia-Pacific is projected to grow fastest over the forecast period.

Why it matters: - Multi-arm polyethylene glycol derivatives are used to improve drug solubility, stability and bioavailability, making them relevant to biologics, vaccines, cell therapies and gene-based treatments. - The market’s growth signals rising demand for advanced drug delivery systems, biomaterials and tissue engineering tools. - The report also points to expanding commercial use beyond healthcare, including cosmetics, personal care and surface coatings.

What happened: - The Business Research Company published a 2026 market report on multi-arm polyethylene glycol (PEG) derivatives. - The report says the market will grow from $6.02 billion in 2025 to $6.72 billion in 2026, a CAGR of 11.6%. - The forecast puts the market at $10.5 billion by 2030, with an 11.8% CAGR. - The report is available in full here, and a free sample is available here.

The details: - The report links historical growth to advances in polymer chemistry, increased pharmaceutical R&D, stronger biomedical research activity, efforts to improve drug formulation stability and broader tissue engineering use. - Future growth is tied to targeted drug delivery, regenerative medicine, tissue engineering, personalized medicine, improved functionalization technologies and greater use in cosmetics and biomaterials. - The report flags escalating demand for functionalized derivatives, more applications in drug delivery and tissue regeneration, progress in bioconjugation and pegylation methods, and expanded diagnostic and medical device use. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, plus updated graphics and tables.

Between the lines: - The report frames multi-arm PEG derivatives as a platform technology rather than a single-use material, which helps explain why demand spans pharmaceuticals, diagnostics, medical devices and consumer products. - Growth in biopharmaceutical and biotechnology investment remains the central engine behind the market outlook. - The employment data cited from GOV.UK, showing 84,800 life sciences employees in the South East of the UK in 2023/2024, is used to illustrate the depth of biomedical activity supporting the category.

What’s next: - The market will likely track progress in biologics, regenerative medicine and personalized treatment platforms. - Adoption should continue rising as more companies look for materials that support controlled chemical modification and better therapeutic performance. - The Business Research Company is also promoting related 2026 reports on adeno-associated virus vectors in gene therapy, gastric cancer therapy and over-the-counter drugs.

The bottom line: - Multi-arm PEG derivatives are moving from a specialty polymer niche into a broader growth market, with healthcare innovation and new industrial uses expected to keep demand rising through 2030.